Kalaris Therapeutics posted a GAAP net loss of USD 11.52 million, versus a GAAP net loss of USD 11.35 million a year earlier.
GAAP R&D expense rose 6.85% to USD 9.02 million, while GAAP G&A expense fell 11.74% to USD 3.37 million.
Cash, cash equivalents and marketable securities totaled USD 93.54 million, down from USD 117.98 million at Dec. 31, 2025.
TH103 clinical program update
Patient dosing continues in the Phase 1b/2 TH103 study; preliminary data is expected in 1H 2027, with Phase 3 initiation targeted by year-end 2027.
CEO Andrew Oxtoby cited new clinical-material batches with process enhancements, following expanded Phase 1a TH103 results supporting prior BCVA, OCT and PK findings.
KLRS•
